TD Cowen initiates Soleno Therapeutics stock with buy rating

TD Cowen initiated coverage on Soleno Therapeutics Inc. (SLNO) with a Buy rating and a $110 price target, highlighting its Vykat XR as the first-approved treatment for hyperphagia in Prader-Willi syndrome. The firm projects significant commercial success for Vykat XR due to its first-in-class status, high pricing potential, and strong market demand, underpinning their $110 DCF-based target. Analysts also anticipate SLNO will achieve profitability this year, a sentiment reinforced by the company's strong liquidity, recent EMA validation for Vykat XR, and consistent positive ratings from other research firms like Piper Sandler, Stifel, and Cantor Fitzgerald.

Analysis

TD Cowen's initiation of coverage on Soleno Therapeutics (SLNO) with a "Buy" rating and a $110 price target highlights a strong bullish case centered on its drug, Vykat XR. As the first-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), Vykat XR holds a monopoly position in a market characterized by high unmet need. The analyst thesis projects significant commercial success driven by a strong launch, premium pricing power, and an urgent patient community, underpinning the DCF-based valuation. This outlook is supported by the company's robust financial health, reflected in a current ratio of 19.64, which provides ample liquidity for the commercial rollout, and analyst expectations for SLNO to achieve profitability this year. The growth trajectory is further reinforced by regulatory momentum, including the European Medicines Agency's (EMA) validation of the drug's Marketing Authorization Application, which opens a path to the EU market where it already has Orphan Drug Designation. This positive sentiment is echoed across Wall Street, with Piper Sandler, Stifel, and Cantor Fitzgerald all maintaining bullish ratings, creating a strong consensus view on the stock's potential.

Key Decisions for Investors

• Given the first-in-class status of Vykat XR, strong analyst consensus, and clear regulatory pathways in the US and EU, investors should assess SLNO's potential as a high-growth biopharmaceutical company transitioning from clinical to commercial stage.
• The primary focus for investors should be on monitoring the initial sales and uptake metrics for Vykat XR post-launch, as these will be the key validation points for the company's revenue potential and the $110 price target.
• Despite the stock's 94% gain over the past year, the analyst price target suggests further upside, but investors must weigh this against the execution risks inherent in any new drug launch and the high expectations already factored into the current market valuation.